Tools & Techniques Cancer, Diagnostics & prognostics

Cells on the (Invasion) Front Lines

The diagnosis and treatment of cancer has moved ahead by leaps and bounds – except when it comes to metastatic disease. Cancer that has spread beyond its origins remains the leading cause of death from the disease, according to the World Health Organization, and although it’s a major focus of research, we know little more about its mechanisms today than we did a decade or more ago. This is especially true when it comes to the epithelial-to-mesenchymal transition (EMT), a key component of the metastatic process… or is it?

The debate over EMT’s significance is a fierce and ongoing one, largely due to the difficulties inherent in observing and understanding it. Why are researchers so convinced of EMT’s role in metastasis? It’s well known that mesenchymal cells are more capable of escaping the primary tumor, and of taking up residence in distant sites. But the evidence against EMT-driven metastasis is mounting, too – most cells in metastatic lesions exhibit epithelial, not mesenchymal, characteristics. Some scientists refer to the reverse process, mesenchymal-to-epithelial transition (MET) to explain this behavior, but others aren’t so sure. At the root of the confusion is a lack of evidence. Until the entire metastatic process – local invasion, intravasation, circulation, arrest and extravasation, proliferation, and angiogenesis – is observed in mesenchymal cells, the role of EMT in metastasis remains an open question.

Despite the debate, many researchers simply take EMT’s role in metastasis as read. Searching the PubMed database for “EMT and metastasis” brings up 3,675 publications, and even Wikipedia – the first port of call for most non-experts without access to peer-reviewed articles – boldly states, “EMT and MET form the initiation and completion of the invasion–metastasis cascade.” There’s little indication of doubt, and yet, recent studies are threatening to completely overhaul the research community’s view of EMT and metastasis. The quest to understand EMT's role is more intense than ever, thanks to groundbreaking new data from research groups whose conclusions go against the grain.

Proceed With Caution

Tracking the Transition

The PDAC Key

First published in The Pathologist (www.thepathologist.com), a sister publication of The Translational Scientist.

Receive content, products, events as well as relevant industry updates from The Translational Scientist and its sponsors.

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

About the Author
Michael Schubert

While obtaining degrees in biology from the University of Alberta and biochemistry from Penn State College of Medicine, I worked as a freelance science and medical writer. I was able to hone my skills in research, presentation and scientific writing by assembling grants and journal articles, speaking at international conferences, and consulting on topics ranging from medical education to comic book science. As much as I’ve enjoyed designing new bacteria and plausible superheroes, though, I’m more pleased than ever to be at Texere, using my writing and editing skills to create great content for a professional audience.

Related Solutions
Powering Proteomics: E-book

| Contributed by SomaLogic

Biomarker Optimization on LabSat® Research

| Contributed by Epredia

One Week to One Day

| Contributed by Epredia

Most Popular
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register